This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
2lfu
From Proteopedia
(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| + | |||
==The structure of a N. meningitides protein targeted for vaccine development== | ==The structure of a N. meningitides protein targeted for vaccine development== | ||
| - | <StructureSection load='2lfu' size='340' side='right' caption='[[2lfu | + | <StructureSection load='2lfu' size='340' side='right'caption='[[2lfu]]' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[2lfu]] is a 1 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[2lfu]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Neisseria_meningitidis Neisseria meningitidis]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2LFU OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2LFU FirstGlance]. <br> |
| - | </td></tr><tr id=' | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2lfu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2lfu OCA], [https://pdbe.org/2lfu PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2lfu RCSB], [https://www.ebi.ac.uk/pdbsum/2lfu PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2lfu ProSAT]</span></td></tr> |
</table> | </table> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/NHBA_NEIME NHBA_NEIME] A major human immunogenic protein detected in patients recovering from meningitidis, where it induces bactericidal antibodies (PubMed:30133484) (By similarity). Binds human cells, heparin and heparan sulfate proteoglycan in vitro via the Arg-rich motif. Heparin-binding to this protein protects bacteria against killing by bactericidal antibodies (serum killing). The bacteria binds a number of human extracellular sialyated and/or sulfated glycans via this protein, including chondroitin sulfate, heparin and ganglioside GT3. Binds DNA non-specifically (By similarity).[UniProtKB:Q7DD37]<ref>PMID:30133484</ref> May play a role in extracellular-DNA (eDNA) mediated biofilm formation. When NHBA is not processed by NalP there is an increase in biofilm formation (PubMed:23163582). Lack of processing may lead to an increase in positively charged, NHBA- and IgA-derived DNA-binding peptides on the cell surface, resulting in increased DNA-binding peptides and increased biofilm formation (Probable).<ref>PMID:23163582</ref> <ref>PMID:23163582</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 19: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Large Structures]] |
| - | [[Category: | + | [[Category: Neisseria meningitidis]] |
| - | [[Category: | + | [[Category: De Chiara C]] |
| - | [[Category: | + | [[Category: Esposito V]] |
| - | [[Category: | + | [[Category: Kelly G]] |
| - | [[Category: | + | [[Category: Musi V]] |
| - | [[Category: | + | [[Category: Pastore A]] |
| - | [[Category: | + | [[Category: Pizza M]] |
| - | [[Category: | + | [[Category: Veggi D]] |
| - | + | ||
Current revision
The structure of a N. meningitides protein targeted for vaccine development
| |||||||||||
